PetVivo’s latest financial statements show a company still in heavy cash-burn mode, with revenue growing unevenly but losses and shareholder dilution remaining the dominant story. Over the last several quarters, the business has continued to generate sales, but operating expenses have consistently far outpaced gross profit. The result is persistent net losses, negative operating cash flow, and repeated reliance on outside financing to stay funded.
On the positive side, revenue is not collapsing. Quarterly revenue has generally held in the low-to-mid hundreds of thousands of dollars, with Q4 2026 revenue of $254,715 versus $297,500 in Q1 2026 and $224,749 in Q4 2025. That suggests the company has some commercial traction, even if the scale is still very small relative to its spending.
Gross margin remains reasonably solid. In Q4 2026, PetVivo posted gross profit of $203,255 on revenue of $254,715, which is a healthy gross margin for a small life-sciences or product company. Earlier quarters also showed meaningful gross profit, indicating the core product economics are not the main issue.
However, expenses continue to overwhelm gross profit by a wide margin. In Q4 2026, operating expenses were $3.17 million against gross profit of just $203,255, producing an operating loss of $2.96 million. That pattern has been consistent across the last several quarters and is the main reason the company remains deeply unprofitable.
Cash flow from operations is consistently negative. Q4 2026 operating cash flow was negative $812,382, while Q3 2026 was negative $1.47 million and Q2 2026 was negative $2.19 million. Even with some non-cash adjustments helping offset losses, the underlying business is still consuming cash.
Financing activity is what keeps the balance sheet afloat. PetVivo has repeatedly raised money through debt and equity. In Q4 2026, financing provided $995,000 of cash, and in prior quarters the company also relied on preferred equity, common equity, and debt issuance. This is a sign the business is dependent on capital markets for survival and growth funding.
Shares outstanding have risen meaningfully over time. Basic shares were 18.7 million in Q1 2025, 20.1 million in Q2 2025, 20.6 million in Q3 2025, 24.3 million in Q1 2026, 27.6 million in Q2 2026, 33.7 million in Q3 2026, and 30.2 million in Q4 2026. That kind of dilution can be a major headwind for existing shareholders.
The balance sheet improved at times thanks to financing, but it remains fragile. Cash and equivalents fell to just $18,164 in Q3 2026 before recovering to $18,164 plus short-term investments of $150,000, and then cash increased modestly again after financing activity. Still, liquidity appears tight relative to ongoing quarterly losses and liabilities.
Liabilities have also remained significant compared with the company’s small revenue base. As of Q3 2026, total liabilities were $997,404 against total equity of $3.38 million. While leverage is not extreme in absolute terms, the business is still not self-funding and depends on external cash infusions.
- Revenue is holding up at a modest level, suggesting PetVivo still has some commercial demand.
- Gross profit remains positive, so the core product economics are not underwater.
- Q4 2026 financing added $995,000 of cash, helping stabilize liquidity in the short term.
- The company continues to report small quarterly revenue, but scale is still very limited.
- Depreciation and other non-cash items reduce the gap between net loss and operating cash flow, but do not solve the underlying cash burn.
- Preferred stock activity and debt issuance remain important parts of the capital structure.
- Operating losses are very large relative to revenue, with Q4 2026 operating loss at $2.96 million.
- Operating cash flow is consistently negative, showing the business is not generating internal cash.
- Share dilution has been substantial over the last year, reducing per-share value for existing holders.
- The company appears dependent on outside capital to fund operations, which raises ongoing financing risk.
Bottom line: PetVivo is still in an early, highly speculative phase. The company has sales and gross profit, but it has not yet proven it can control expenses or generate positive cash flow. For retail investors, the key risks are continued losses, dilution, and reliance on financing rather than operating performance.
07/18/26 02:12 PM ETAI Generated. May Contain Errors.
